Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ c-Cbl Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA19022
Description
This antibody is predicted to react with bovine, canine, human, porcine and rat based on sequence homology. This antibody is tested in Peptide ELISA: antibody detection limit dilution 32,000.
Cbl proteins are a family of ubiquitin protein ligases (E3s) that negatively regulate signaling by targeting activated tyrosine kinases for degradation. Cbl- c is the most recently cloned member of the Cbl proteins and is expressed only in epithelial cells (the other Cbl proteins are ubiquitously expressed). Cbl-c, like the other mammalian Cbl proteins, can ubiquitinate the activated EGFR and target it for degradation. Through interactions with proteins containing SRC homology-2 (SH2) and SH3 domains, CBL proteins modulate downstream cell signaling.
Specifications
c-Cbl | |
Polyclonal | |
Unconjugated | |
Cbl | |
4732447J05Rik; Cas-Br-M (murine) ecotropic retroviral transforming sequence; Casitas B-lineage lymphoma; casitas B-lineage lymphoma proto-oncogene; CBL; Cbl proto-oncogene; Cbl proto-oncogene, E3 ubiquitin protein ligase; CBL2; Cbl-2; CBL-3; CBLC; c-Cbl; E3 ubiquitin-protein ligase CBL; FRA11B; fragile site, folic acid type, rare, fra(11)(q23.3); NSLL; oncogene CBL2; proto-oncogene c-Cbl; RGD1561386; RING finger protein 55; RING-type E3 ubiquitin transferase CBL; RNF55; RNF57; signal transduction protein CBL | |
Goat | |
Ammonium Sulfate Precipitation | |
RUO | |
12402, 500985, 867 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot, Immunocytochemistry | |
0.5 mg/mL | |
TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
P22681, P22682 | |
Cbl | |
Synthetic peptide corresponding to the C terminus amino acids REFVSISSPAHVAT (aa 893-906). | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction